Can't value all companies the same.
Case in point
CCL P/E 25
IRE P/E 35
A2M has a greater growth profile. Just because a company has hit 25-35 P/E it means it overvalued. On the contrary could be undervalued.
A2M FY21 estimates at current levels is at 23 P/E. If FY 20 surpases NZ 0.45c EPS then FY 21 will be upgraded.
You can't put all stocks in the same basket and value them the same way. Question is, has A2M reached its peak growth rate and hit top end of bell curve?
Well I don't think it has - I believe alot of negativity is priced in which allows for upside surprises. I currently value A2M around $15.50 based on FY 21 estimates which is around NZ 0.56 EPS.
- Forums
- ASX - By Stock
- A2M
- Chart Update
Chart Update, page-8523
-
- There are more pages in this discussion • 16,708 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add A2M (ASX) to my watchlist
|
|||||
Last
$6.85 |
Change
-0.030(0.44%) |
Mkt cap ! $4.952B |
Open | High | Low | Value | Volume |
$6.93 | $6.98 | $6.83 | $10.27M | 1.490M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 18844 | $6.84 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.85 | 41602 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 11039 | 6.840 |
1 | 3000 | 6.830 |
4 | 17920 | 6.820 |
4 | 9541 | 6.810 |
2 | 5020 | 6.800 |
Price($) | Vol. | No. |
---|---|---|
6.850 | 41602 | 1 |
6.860 | 548 | 1 |
6.870 | 8050 | 3 |
6.880 | 16820 | 3 |
6.890 | 5115 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
A2M (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online